CelLBxHealth shares jump on forecast for 50% revenue growth in 2026

(Alliance News) - CelLBxHealth PLC on Monday said it expects at least 50% revenue growth in 2026 as it advances its turnaround strategy and continues to reduce costs.

The Guildford, England-based liquid biopsy company, formerly called Angle PLC, said first-quarter trading reflected an initial focus on organisational restructuring under its revised business strategy.

Shares in CelLBxHealth were up 27% at 1.30 pence in London on Monday afternoon.

CelLBxHealth said it reduced headcount further to 39 full-time employees from 44 during the quarter, following a 60% reduction in staff last year.

The company said the restructuring and additional cost-saving measures are expected to reduce annual cash operating costs in 2026 by more than GBP6.6 million. Further planned cost reductions in the second quarter are expected to generate an additional GBP100,000 in savings.

Cash at March 31 stood at GBP4.3 million, in line with company expectations and reflecting one-off restructuring costs.

Looking ahead, CelLBxHealth said it remains focused on commercial progress and revenue growth, including the appointment of a new head of sales in the US.

The company said it expects revenue for financial 2026 of at least GBP2.1 million, which would represent growth of around 50% from 2025, supported by contracted revenue and expected sales conversions.

CelLBxHealth said its qualified sales pipeline continues to build and noted there are additional opportunities that could support a future upgrade to guidance.

The company also said it is in advanced discussions with one of the largest private US healthcare providers regarding the use of its Parsortix platform in two clinical studies.

In addition, CelLBxHealth said it is in the final stages of concluding a master services agreement with a top ten global pharmaceutical company to potentially support drug discovery and development using the Parsortix platform.

The company also completed a sublease agreement for part of its US facility.

Chief Executive Officer Peter Collins said the board remains confident of delivering "significant growth in 2026 and beyond".

By Eva Castanedo, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Cellbxhealth